/DaVita%20Inc%20sign%20on%20building-by%20photo-denver%20via%20Shutterstock.jpg)
While DaVita has outperformed the broader market over the past year, analysts on Wall Street are exercising caution regarding its future prospects.
The company's profitability is going in the wrong direction for many investors.
DVA earnings call for the period ending September 30, 2024.
Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and...
Cencora, Inc. COR witnessed strong momentum in the year-to-date period. Shares of the company have rallied 14.7% compared with 2.8% growth of the industry. The S&P 500 Composite has risen 22.5% during...
DaVita is all set to release its third-quarter earnings this month, and analysts expect a single-digit profit dip.
Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a Contract...
Becton, Dickinson and Company BDX, popularly known as BD, announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits, BD OMICS-One XT Library Preparation...
Smith & Nephew SNATS SNN recently announced the signing of a co-marketing agreement with JointVue for its patented OrthoSonic 3D Surgery Planning Technology, which is the only ultrasound device currently...
DaVita Inc. DVA has been gaining from its business model. The optimism, led by a solid second-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further. However,...